Difference between revisions of "MDMA"
| Line 16: | Line 16: | ||
'''Action and Measurement''' | '''Action and Measurement''' | ||
The negative experience of "comedowns", colloquially known as "Blue Mondays," are often anecdotally reported by people who take MDMA. Research by Sessa et al. suggests that MDMA comedowns do not exist in a clinical environment and should instead be attributed to improper dosing and illicit sourcing. <ref>Ben Sessa et al., “Debunking the Myth of ‘Blue Mondays’: No Evidence of Affect Drop after Taking Clinical MDMA,” ''Journal of Psychopharmacology'' 36, no. 3 (March 2022): 360–67, <nowiki>https://doi.org/10.1177/02698811211055809</nowiki>.</ref> | MDMA significantly improves sleep quality in those with post-traumatic-stress-disorder as far as twelve months out from initial treatment. <ref>Linnae Ponte et al., “Sleep Quality Improvements After MDMA‐Assisted Psychotherapy for the Treatment of Posttraumatic Stress Disorder.,” ''Journal of Traumatic Stress'' 34, no. 4 (August 2021): 851–63.</ref> | ||
The negative experience of "comedowns", colloquially known as "Blue Mondays," are often anecdotally reported by people who take MDMA. Research by Sessa et al. suggests that MDMA comedowns do not exist in a clinical environment and should instead be attributed to improper dosing and illicit sourcing. <ref>Ben Sessa et al., “Debunking the Myth of ‘Blue Mondays’: No Evidence of Affect Drop after Taking Clinical MDMA,” ''Journal of Psychopharmacology'' 36, no. 3 (March 2022): 360–67, <nowiki>https://doi.org/10.1177/02698811211055809</nowiki>.</ref> | |||
As Rigg et al. notes, MDMA related deaths (MRDs) are not due to inherent dangers with the substance nor attributed to overdose. Instead, they are caused by relating factors such as "hyperthermia, dehydration, drug interactions, or hyponaetremia". Similarly to Sessa et al. this stems from incorrect testing, sourcing, and ingestion. <ref>Khary K. Rigg and Amanda Sharp, “Deaths Related to MDMA (Ecstasy/Molly): Prevalence, Root Causes, and Harm Reduction Interventions.,” ''Journal of Substance Use'' 23, no. 4 (July 2018): 345–52, <nowiki>https://doi.org/10.1080/14659891.2018.1436607</nowiki>. p. 345.</ref> | |||
==Effects== | ==Effects== | ||
Revision as of 21:43, 8 January 2023
MDMA is an extremely powerful Entactogen that temporarily suppresses the body's fear and anxiety response thus enabling one to recognize and process even deeply buried traumatic experiences.
List of Connection Supplements
Connection Supplement > 5-MEO DMT, Ayahuasca, Cannabis, Chloroform, DMT, Datura, Haoma, Kaneh Bosm, Kava, Ketamine, Kykeon, LSD, MDMA, Maikua, Manna, Nitrous Oxide, Peyote, Psilocybin Mushroom, Santa Rosa, Soma, Tobacco, Yaqona
Notes
MDMA is not a recreational drug and should not be used as such. MDMA is a powerful psychoactive that is extremely useful for healing even deep trauma.
MDMA is a "breakthrough" therapy for PTSD.[1]
MDMA has a "strong bias toward the positive end of the affective spectrum, deeply heart-full, centered psychological insight and self-aceptance, and tends to produce less visual imagery or 'cosmic'breakthroughs or metaphysical disorientation."[2]
Action and Measurement
MDMA significantly improves sleep quality in those with post-traumatic-stress-disorder as far as twelve months out from initial treatment. [3]
The negative experience of "comedowns", colloquially known as "Blue Mondays," are often anecdotally reported by people who take MDMA. Research by Sessa et al. suggests that MDMA comedowns do not exist in a clinical environment and should instead be attributed to improper dosing and illicit sourcing. [4]
As Rigg et al. notes, MDMA related deaths (MRDs) are not due to inherent dangers with the substance nor attributed to overdose. Instead, they are caused by relating factors such as "hyperthermia, dehydration, drug interactions, or hyponaetremia". Similarly to Sessa et al. this stems from incorrect testing, sourcing, and ingestion. [5]
Effects
Footnotes
- ↑ Mitchell, Jennifer M., Michael Bogenschutz, Alia Lilienstein, Charlotte Harrison, Sarah Kleiman, Kelly Parker-Guilbert, Marcela Ot’alora G., et al. “MDMA-Assisted Therapy for Severe PTSD: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study.” Nature Medicine 27, no. 6 (June 1, 2021): 1025–33. https://doi.org/10.1038/s41591-021-01336-3.
- ↑ Olivetti, Katherine. “Dimensions of the Psyche.” Jung Journal 9, no. 4 (October 2, 2015): 98–124. https://doi.org/10.1080/19342039.2015.108693 p. 103
- ↑ Linnae Ponte et al., “Sleep Quality Improvements After MDMA‐Assisted Psychotherapy for the Treatment of Posttraumatic Stress Disorder.,” Journal of Traumatic Stress 34, no. 4 (August 2021): 851–63.
- ↑ Ben Sessa et al., “Debunking the Myth of ‘Blue Mondays’: No Evidence of Affect Drop after Taking Clinical MDMA,” Journal of Psychopharmacology 36, no. 3 (March 2022): 360–67, https://doi.org/10.1177/02698811211055809.
- ↑ Khary K. Rigg and Amanda Sharp, “Deaths Related to MDMA (Ecstasy/Molly): Prevalence, Root Causes, and Harm Reduction Interventions.,” Journal of Substance Use 23, no. 4 (July 2018): 345–52, https://doi.org/10.1080/14659891.2018.1436607. p. 345.
